Given that dipeptidyl peptidase-4 inhibitors (DPP4i) are the most widely used antidiabetic medication following metformin in routine clinical practice [24–26], it would be relevant to compare the effects of SGLT2i with DPP4i in diabetic patients without prior ASCVD, CKD, or HF, in order to assess a class effect for SGLT2i. This evidence concerns the gene DPP4 and chronic kidney disease.